India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Lofty has launched the industry’s first Agentic AI Operating System, a breakthrough platform that doesn’t just follow commands—it plans, executes, evaluates, and adapts entire workflows on its own. Designed specifically for real estate professionals, the system acts like an AI “orchestra,” coordinating specialized agents for lead qualification, marketing, SEO, transaction management, website creation, and more. With leaders calling this a major leap beyond traditional tools, Lofty AOS signals a new era where agents can focus on relationships and closings while AI handles the heavy lifting.
Florida’s insurance landscape is finally showing signs of stability as private insurers return and Citizens Property Insurance drops below 400,000 policies. Insurance Commissioner Michael Yaworsky says reforms are working, but homeowners may not feel relief yet as inflation and rebuilding costs keep premiums high. With transparency improvements, mitigation credits, and new AI regulations on the horizon, Florida aims to avoid another insurance crisis while keeping the market competitive and consumer‑friendly.
Mortgage rates just hit their lowest point since 2022, closing January at 6.18% and giving buyers and industry professionals a rare moment of relief. But while the Federal Reserve continues to pause rate hikes, economists warn that significant declines are unlikely. Most forecasts show rates hovering near 6% through 2026, with political uncertainty and inflation keeping markets volatile. For now, stability may be the best we get — and even that could be temporary.
Propy, a fast-growing real estate tech firm blending AI automation with blockchain-backed transaction systems, has secured a major $100 million credit facility to accelerate nationwide title company consolidation. The funding aims to modernize the traditionally slow, paper-heavy closing process, offering real estate professionals a faster, more secure, and more transparent experience. As automation reshapes the industry, staying educated on emerging technology will be essential for agents, brokers, mortgage professionals, and investors looking to stay competitive.
Escrow payments in Florida have jumped an astonishing 70% since 2019, far outpacing the national average and now consuming nearly 38% of a typical monthly mortgage payment. Surging insurance premiums and rising property taxes are driving the increase, reshaping affordability for homeowners and pricing out many would‑be buyers.
After losing their Altadena home in the LA wildfires, Jessica and Matt Conkle expected State Farm to help them rebuild. Instead, they faced months of delays, low valuations, and stalled claims — a struggle shared by nearly 80 percent of wildfire survivors. As insurers pull out of high‑risk areas and premiums soar, the crisis is reshaping homeownership, tightening mortgage approvals, and straining government safety nets. What’s happening in California is rapidly becoming a national issue, with real estate, mortgage, and insurance professionals on the front lines of a system under unprecedented pressure.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
